Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 521,890
  • Shares Outstanding, K 38,860
  • Annual Sales, $ 1,540 K
  • Annual Income, $ -135,750 K
  • 36-Month Beta 1.08
  • Price/Sales 350.65
  • Price/Cash Flow 0.00
  • Price/Book 17.57

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.79 +13.91%
on 05/10/17
15.88 -15.43%
on 05/16/17
+0.93 (+7.44%)
since 04/26/17
3-Month
8.58 +56.53%
on 03/07/17
15.88 -15.43%
on 05/16/17
+3.49 (+35.11%)
since 02/24/17
52-Week
7.00 +91.86%
on 06/27/16
15.88 -15.43%
on 05/16/17
+4.60 (+52.10%)
since 05/26/16

Most Recent Stories

More News
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

SGMO : 7.25 (-7.05%)
AKBA : 13.43 (-3.03%)
VRTX : 119.92 (+1.11%)
IONS : 46.38 (+0.06%)
REGN : 455.17 (-0.12%)
ALXN : 97.70 (-0.81%)
BIIB : 250.80 (-0.86%)
Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

Vifor Pharma Ltd. / Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval . Processed and transmitted by Nasdaq Corporate...

AKBA : 13.43 (-3.03%)
Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

--- Additional Funds Support Vadadustat Global Development Program to Data a^'

AKBA : 13.43 (-3.03%)
Akebia Announces First Quarter 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%

Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.

AKBA : 13.43 (-3.03%)
GRFS : 21.36 (-0.23%)
American Kidney Fund Receives Funding Support to Expand Popular 'ACT on Anemia' Education Program to Reach Spanish Speakers

The American Kidney Fund (AKF) today announced it has received funding support to expand its popular "ACT on Anemia" program by creating new Spanish-language web content and educational materials, along...

AKBA : 13.43 (-3.03%)
Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialise Vadadustat in Europe, China and Other Territories

--- Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, including $208 million or more in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties...

AKBA : 13.43 (-3.03%)
Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories

--Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, Including $208 million or More in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties...

AKBA : 13.43 (-3.03%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.43 (-3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Support & Resistance

2nd Resistance Point 14.01
1st Resistance Point 13.72
Last Price 13.43
1st Support Level 13.25
2nd Support Level 13.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.